Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Novavax, Inc.

A Decade of SG&A Trends: Alnylam vs. Novavax

In the ever-evolving pharmaceutical landscape, operational efficiency is key. Over the past decade, Alnylam Pharmaceuticals and Novavax have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Alnylam's SG&A costs have surged by over 1,600% from 2014 to 2023, reflecting its aggressive expansion and strategic investments. In contrast, Novavax's expenses grew by approximately 2,300% during the same period, highlighting its rapid scaling efforts, especially during the pandemic years.

Key Insights

• Alnylam Pharmaceuticals: From 2014 to 2023, Alnylam's SG&A expenses increased steadily, peaking in 2023, indicating a consistent growth strategy.
• Novavax, Inc.: Notably, Novavax's SG&A expenses spiked significantly in 2021 and 2022, aligning with its pivotal role in COVID-19 vaccine development.

These trends underscore the dynamic nature of the pharmaceutical industry, where strategic financial management can drive growth and innovation.